Riesgo oncológico e infección COVID-19 en mujeres usuarias de anticonceptivos hormonales.

Abstract

Introduction: COVID-19 is the cause of several alterations in coagulation which can be increased by the use of contraceptives. Likewise, its administration is associated with an increased oncological risk for some cancers, but it has a certain level of protection against others. Oncology patients are at increased risk of COVID-19 infection, but no association between hormonal contraceptive use, COVID-19 and oncologic risk has been reported. Objective: To identify key characteristics of oncologic risk and COVID-19 infection among hormonal contraceptive users. Methods: A correlational, descriptive and systematic study, based on a review of 42 documents between the years 2020-2022, containing clear and concrete information on the subject, in English and Spanish. Results: Out of a total of 50 articles found, 42 documents were selected, in English and Spanish, that appropriately met the exclusion and inclusion criteria. Discussion: The provision of contraceptives should be done after evaluation of thromboembolic and oncologic risks. Patients with cancer have a greater predisposition to contract COVID-19 and present severe symptoms, but there is no evidence as to whether the use of contraceptives affects the presentation or prognosis of cancer in patients infected with this virus. Conclusions: There is no evidence to determine a correlation of increased cancer risk in patients using contraceptives with COVID-19 infection.